Regenexx are competitors. The difference is that they inject the patient with his own stem cells. This process is not FDA approved. In fact Regenexx are in fighting the FDA, on the basis that it is a surgical procedure and therefore not an FDA issue. So there has not been any trials that prove their assertions about efficacy. In fact you will find very little authoritive unbiased imformation about Regenexx. So they have a vested interest in baggging MSB. Never the less, I would like a clinician to evaluate the article by them.
credible critique or not?, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |